Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

被引：6

作者：

Manuel Sousa, Jose ^{[1
]}

Vergara, Mercedes ^{[2
,3
]}

Pulido, Federico ^{[4
]}

Sanchez Antolin, Gloria ^{[5
]}

Hijona, Lander ^{[6
]}

Carnicer, Fernando ^{[7
]}

Rincon, Diego ^{[8
,9
]}

Salmeron, Javier ^{[10
]}

Mateos-Munoz, Beatriz ^{[11
]}

Jou, Antoni ^{[12
,13
]}

Polo-Lorduy, Benjamin ^{[14
]}

Rubin, Angel ^{[15
]}

Escarda, Ana ^{[16
]}

Aguilar, Patricia ^{[17
]}

Aldamiz-Echevarria, Teresa ^{[18
]}

Garcia-Buey, Luisa ^{[19
]}

Carrion, Jose A. ^{[20
]}

Hernandez-Guerra, Manuel ^{[21
]}

Chimeno-Hernandez, Sonia ^{[22
]}

Espinosa, Nuria ^{[23
]}

Morillas, Rosa Ma ^{[24
,25
]}

Andrade, Raul J. ^{[26
]}

Delgado, Manuel ^{[27
]}

Gallego, Adolfo ^{[28
]}

Magaz, Marta ^{[29
]}

Maria Moreno-Planas, Jose ^{[30
]}

Estebanez, Angel ^{[31
]}

Rico, Mikel ^{[32
]}

Menendez, Fernando ^{[33
]}

Sampedro, Blanca ^{[34
]}

Morano, Luis ^{[35
]}

Izquierdo, Sonia ^{[36
]}

Manuel Zozaya, Jose ^{[37
]}

Rodriguez, Manuel ^{[38
]}

Moran-Sanchez, Senador ^{[39
]}

Lorente, Sara ^{[40
]}

Martin-Granizo, Ignacio ^{[41
]}

Angel Von-Wichmann, Miguel ^{[42
]}

Delgado, Marcial ^{[43
]}

Manzanares, Amanda ^{[44
]}

机构：

[1] Hosp Univ Virgen del Rocio, Hepatol Dept, Seville, Spain

[2] Parc Tauli Sabadell Hosp Univ, Digest Dis Dept, Hepatol Unit, Barcelona, Spain

[3] Inst Carlos III, CIBERehd, Madrid, Spain

[4] Univ Complutense Madrid UCM, HIV Unit, Imas12, Hosp Univ 12 Octubre, Madrid, Spain

[5] Hosp Univ Rio Hortega, Hepatol Dept, Valladolid, Spain

[6] Hosp Univ Araba, Hepatol Dept, Vitoria, Alava, Spain

[7] Hosp Gen Univ Alicante, Hepatol Dept, Alicante, Spain

[8] Hosp Gen Univ Gregorio Maranon, Hepatol Dept, CIBERehd, Madrid, Spain

[9] UCM, Madrid, Spain

[10] Complejo Hosp Univ Granada, Hepatol Dept, Granada, Spain

[11] Hosp Univ Ramon y Cajal, Hepatol Dept, Madrid, Spain

[12] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Internal Med Dept, HIV Clin Unit, Barcelona, Spain

[13] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Fundacio Lluita SIDA, Barcelona, Spain

[14] Hosp Univ Fdn Jimenez Diaz, Hepatol Dept, Madrid, Spain

[15] Hosp Univ & Politecn La Fe, Hepatol Dept, Valencia, Spain

[16] Hosp Univ Son Espases, Hepatol Dept, Palma De Mallorca, Spain

[17] Cordoba Univ, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, Digest Syst Clin Unit, Cordoba, Spain

[18] Hosp Gen Univ Gregorio Maranon IiSGM, Infect Dis HIV, Madrid, Spain

[19] Hosp Univ La Princesa, Hepatol Dept, Madrid, Spain

[20] UAB Univ Autonoma Barcelona Barcelona, Hosp del Mar, IMIM Hosp del Mar Med Res Inst, Gastroenterol Dept,Liver Sect, Barcelona, Spain

[21] Hosp Univ Canarias, Hepatol Dept, San Cristobal la Laguna, Santa Cruz De T, Spain

[22] Hosp Arnau Vilanova, Hepatol Dept, Valencia, Spain

[23] Univ Seville, Inst Biomed Seville IBiS, Clin Unit Infect Dis Microbiol & Prevent Med, CSIC,Infect Dis Res Grp, Seville, Spain

[24] Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol, Liver Sect, IGTP, Barcelona, Spain

[25] CIBEREHD, Barcelona, Spain

[26] Univ Malaga, Hosp Univ Virgen de la Victoria, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed Malaga IBIMA,Unidad Gest Clin, Malaga, Spain

[27] Complejo Hosp Univ A Coruna, Hepatol Dept, La Coruna, Spain

[28] Hosp Santa Creu & Sant Pau, Hepatol Dept, Barcelona, Spain

[29] Hosp Univ Puerta de Hierro Majadahonda, Hepatol Dept, Madrid, Spain

[30] Complejo Hosp Univ Albacete, Digest Syst Dept, Albacete, Spain

[31] Hosp Univ Marques de Valdecilla, Hepatol Dept, Santander, Cantabria, Spain

[32] Hosp Univ La Paz, Infect Dis Unit, Madrid, Spain

[33] Hosp Univ Basurto, Hepatol Dept, Bilbao, Vizcaya, Spain

[34] Hosp Galdakao, Hepatol Dept, Galdakao, Vizcaya, Spain

[35] Hosp Univ Alvaro Cunqueiro, Infect Dis Unit, Vigo, Pontevedra, Spain

[36] Hosp Clin San Carlos, Hepatol Dept, Madrid, Spain

[37] Complejo Hosp Navarra, Hepatol Dept, Pamplona, Navarra, Spain

[38] Hosp Univ Cent Asturias, Div Gastroenterol & Hepatol, Liver Unit, Oviedo, Asturias, Spain

[39] Hosp Gen Univ Santa Lucia, Hepatol Dept, Murcia, Spain

[40] Hosp Clin Univ Lozano Blesa, Hepatol Dept, Zaragoza, Spain

[41] Hosp Univ Alvaro Cunqueiro, Dept Gastroenterol, Vigo, Pontevedra, Spain

[42] Hosp Univ Donostia, Infect Dis Unit, Donostia San Sebastian, Gipuzkoa, Spain

[43] Hosp Reg Univ Malaga, Infect Dis Unit, Malaga, Spain

[44] AbbVie Spain SLU, Madrid, Spain

来源：

PLOS ONE | 2019年 / 14卷 / 11期

关键词：

TREATMENT-EXPERIENCED PATIENTS; GENOTYPE; INFECTION; ABT-450/R-OMBITASVIR; HCV; OMBITASVIR/PARITAPREVIR/RITONAVIR; PREVALENCE; RITONAVIR; SAFETY;

D O I：

10.1371/journal.pone.0225061

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Aim We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r +/- DSV +/- RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain. Material and methods Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r +/- DSV +/- RBV at 61 Spanish sites within the initial implementation year of the first government-driven "National HCV plan." Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded. Results Overall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8-97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of -2.2% (90% CI, -4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r +/- DSV +/- RBV treatment (p < 0.001) in the multivariate analysis. Overall, 286 patients (11.9%) presented AEs potentially related to OBV/PTV/r +/- DSV, whereas 347 (29.0%) presented AEs potentially related to ribavirin and 61 (5.1%) interrupted ribavirin. Conclusions Our results confirm that OBV/PTV/r +/- DSV +/- RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.

引用

页数：18

共 50 条

[1] REAL-WORLD SAFETY AND EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/R WITH DASABUVIR AND/OR RIBAVIRIN IN THE GERMAN HEPATITIS C REGISTRY
Hinrichsen, H.
Wedemeyer, H.
Christensen, S.
Sarrazin, C. M.
Baumgarten, A.
Mauss, S.
Hettinger, J.
Kleine, H.
JOURNAL OF HEPATOLOGY, 2016, 64 : S159 - S159
[2] Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients
Nicole Loo
Eric Lawitz
Naim Alkhouri
Jennifer Wells
Carmen Landaverde
Angie Coste
Rossalynn Salcido
Michael Scott
Fred Poordad
World Journal of Gastroenterology, 2019, (18) : 2229 - 2239
[3] Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
Flisiak, R.
Janczewska, E.
Wawrzynowicz-Syczewska, M.
Jaroszewicz, J.
Zarebska-Michaluk, D.
Nazzal, K.
Bolewska, B.
Bialkowska, J.
Berak, H.
Fleischer-Stepniewska, K.
Tomasiewicz, K.
Karwowska, K.
Rostkowska, K.
Piekarska, A.
Tronina, O.
Madej, G.
Garlicki, A.
Lucejko, M.
Pisula, A.
Karpinska, E.
Kryczka, W.
Wiercinska-Drapalo, A.
Mozer-Lisewska, I.
Jablkowski, M.
Horban, A.
Knysz, B.
Tudrujek, M.
Halota, W.
Simon, K.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (09) : 946 - 956
[4] Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
Liu, Chen-Hua
Liu, Chun-Jen
Su, Tung-Hung
Yang, Hung-Chih
Hong, Chun-Ming
Tseng, Tai-Chung
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 710 - 717
[5] Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study
Simon, Krzysztof Adam
Flisiak, Robert
Lapinski, Tadeusz Wojciech
Janczewska, Ewa
Wawrzynowicz-Syczewska, Marta
Jaroszewicz, Jerzy
Zarebska-Michaluk, Dorota
Nazzal, Khalil
Bolewska, Beata
Bialkowska, Jolanta
Berak, Hanna
Fleischer-Stepniewska, Katarzyna
Tomasiewicz, Krzysztof
Karwowska, Kornelia
Rostkowska, Karolina Anna
Piekarska, Anna
Tronina, Olga
Madej, Grzegorz
Garlicki, Aleksander
Lucejko, Mariusz
Pisula, Arkadiusz
Karpinska, Ewa
Kryczka, Wieslaw
Wiercinska-Drapalo, Alicja
Mozer-Lisewska, Iwona
Jablkowski, Maciej Stanislaw
Horban, Andrzej
Knysz, Brygida
Tudrujek, Magdalena
Halota, Waldemar
CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 5 (03) : 215 - 223
[6] Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis
Wedemeyer, H.
Craxi, A.
Zuckerman, E.
Dieterich, D.
Flisiak, R.
Roberts, S. K.
Pangerl, A.
Zhang, Z.
Martinez, M.
Bao, Y.
Calleja, J. -L.
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (11) : 936 - 943
[7] Real-world efficacy and safety of ombitasvir, paritaprevir/r plus dasabuvir plus ribavirin in genotype 1b patients with hepatitis C virus cirrhosis
Preda, Carmen M.
Popescu, Corneliu P.
Baicus, Cristian
Voiosu, Theodor A.
Manuc, Mircea
Pop, Corina Silvia
Gheorghe, Liana
Sporea, Ioan
Trifan, Anca
Tantau, Marcel
Tantau, Alina
Ceausu, Emanoil
Proca, Doina
Constantinescu, Ileana
Ruta, Simona M.
Diculescu, Mircea M.
Oproiu, Alexandru
LIVER INTERNATIONAL, 2018, 38 (04) : 602 - 610
[8] Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus /- ribavirin in real world hepatitis C patients
Loo, Nicole
Lawitz, Eric
Alkhouri, Naim
Wells, Jennifer
Landaverde, Carmen
Coste, Angie
Salcido, Rossalynn
Scott, Michael
Poordad, Fred
WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (18) : 2229 - 2239
[9] Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient
Sollima, Salvatore
Milazzo, Laura
Torre, Alessandro
Calvi, Elisa
Regalia, Enrico
Antinori, Spinello
LIVER TRANSPLANTATION, 2016, 22 (02) : 252 - 253
[10] Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience
Yu, Ming-Lung
Chen, Yao-Li
Huang, Chung-Feng
Lin, Kuo-Hua
Yeh, Ming-Lun
Huang, Ching-I
Hsieh, Meng-Hsuan
Lin, Zu-Yau
Chen, Shinn-Cherng
Huang, Jee-Fu
Dai, Chia-Yen
Chuang, Wan-Long
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (06) : 518 - 526

← 1 2 3 4 5 →